Skip to main content
Globalization and Health logoLink to Globalization and Health
. 2021 Apr 12;17:45. doi: 10.1186/s12992-021-00696-2

Alcohol marketing versus public health: David and Goliath?

Mary Madden 1,, Jim McCambridge 1
PMCID: PMC8040366  PMID: 33845851

Abstract

Background

Alcohol harms are rising globally, and alcohol policies, where they exist, are weak or under-developed. Limited progress has been made since the formulation of the World Health Organisation (WHO) Global Strategy in 2010. WHO is seeking to accelerate progress in implementing international efforts to reduce the harmful use of alcohol. The threat to global health posed by tobacco is well understood by policy communities and populations globally; by contrast alcohol is much less so, despite available evidence.

The competition for epistemic authority

Global alcohol corporations have sought to become trusted sources of advice for policy makers and consumers, while continuing to grow their markets. Evidence-informed public health messaging faces formidable competition from transnational corporations as the worlds of corporate and political communications, social and mainstream media become increasingly linked, presenting new opportunities for corporate actors to shape global health governance. Alcohol messaging that uses means of persuasion tied to industry agendas does not tell a clear story about commercial determinants of health, and does not contribute to health improvement. On the contrary, the basic tenets of an evidence-informed population-based approach are denied and the policy measures supported by high quality evidence are being opposed, because they are inimical to commercial interests. A David and Goliath metaphor for this state of affairs, which seems to fit at first glance, may unwittingly reinforce the status quo.

Conclusion

Public opinion on alcohol and policy issues varies across time and place and can be influenced by dedicated public health interventions. Alcohol marketing dominates people’s thinking about alcohol because we currently allow this to happen. Greater ambition is needed in developing countermarketing and other interventions to promote evidence-informed ideas with the public. Alcohol policies need to be further developed, and implemented more widely, in order to arrest the growing burden of alcohol harms across the world.

Keywords: Commercial determinants of health, Alcohol, Public health, Alcohol marketing, Alcohol industry, Alcohol policy, Global health

Background

Alcohol policies, where they exist, are usually weak or under-developed in the face of the challenges with which they contend [1]. The current global annual death toll of 3 million is forecast to rise, particularly in low and middle income countries [2]. A minority of the world’s population drinks alcohol, so there is a large market to be developed [1]. A small number of corporations now produce most of the beer and spirits consumed across the world, creating an oligopoly [3]. Building consumer relationships with distinctive brands, creatively tailored to appeal to targeted audiences, helps provide competitive edge for individual companies [4]. This also conveys a sense of proliferating choice, even when innovations in production are absent. The worlds of corporate and political communications, social and mainstream media have become increasingly linked, presenting new opportunities for corporate actors to shape global health governance [5]. Extensive resources are deployed to exploit these opportunities and close relationships are built with key political actors through lobbying [6]. It is a marketing truism that those who set the frame control the agenda [7].

Evidence-informed public health messaging thus faces formidable competition from transnational alcohol corporations. This resembles in part a contest over epistemic authority, as corporations seek to become trusted sources of advice for policy makers and consumers, while continuing to grow their markets [8]. There is a growing mismatch between the expansion of global markets and efforts at national regulation [9]. A World Health Organisation (WHO) Action plan (2022–2030) is now proposed to accelerate progress in implementing international efforts to reduce the harmful use of alcohol [10]. This is needed because of the limited progress made since the formulation of a Global Strategy in 2010 [11, 12]. It can sometimes seem to public health interests that they are David, daring to hope to win against the odds, and the corporation is Goliath. Given that the actions that need to be taken are largely well established in the alcohol policy evidence, David should be winning by now. To get off the back foot, we need to further develop our understanding of the changing nature of the challenge.

The competition for epistemic authority

No level playing field

Corporate communication campaigns are now not only about introducing and seeking views on particular products and brands, but leading opinion more broadly in market friendly directions [13]. Corporate communicators take a strategic approach to the identification and segmentation of publics, cultivating relationships to influence consumer and public opinion and promoting reasons to care about brands and industry interests [14]. Because of the harmful nature of their products, alcohol producers are deeply invested in branding themselves as good corporate citizens [15, 16]. Corporate social responsibility initiatives like Drinkaware in the UK work as a form of implicit alcohol industry branding, managing conflicts between corporate and public health interests [1720]. Such initiatives are produced within a corporate market logic focused on sustaining profit growth which indirectly promotes product consumption as responsible and normal [19, 21].

As well as publishing misinformation for the public [22, 23], the alcohol industry also funds and publishes research which casts doubt on scientific evidence about product harms and policy responses, some of which is designed to emphasise purported benefits [2426]. The basic tenets of an evidence-informed population-based approach are denied and the policy measures supported by high quality evidence are opposed, because they are inimical to commercial interests [27, 28]. Extensive political lobbying and stakeholder marketing has created key networks and partnerships in many countries and, together with free market think tanks, provided persuasive rationales to secure preferred policy directions [8, 29]. The power imbalance raises important market ethics issues [30], as well as obvious public health policy issues.

Corporate investment in shaping drinking norms and distracting from evidence on alcohol harms amounts to the cultivation of ignorance, as pioneered by the tobacco industry [31, 32]. The tobacco playbook has been adopted by other industries [33], and there are deep historical links between alcohol and tobacco companies [34, 35]. There is recent evidence of tobacco and alcohol collaborative efforts to undercut the credibility of science [36] and they have long sought to influence policy together [37]. This helps to explain why alcohol has been appositely described as a global health blind spot [38].

Alcohol exceptionalism

The threat to global health posed by tobacco is well understood; alcohol much less so, despite a substantial epidemiological evidence base identifying it as a major contributor to the global burden of disease, disability and death [39]. The alcohol and tobacco industries depend on addiction and other harmful forms of consumption in their operating models, and make products that harm others as well as the individual consumer [40, 41]. ‘Tobacco exceptionalism’ refers to the ways we think of the tobacco industry and its products as uniquely dangerous, and in need of a unique model of governance [42]. Thinking about the alcohol industry in such ‘exceptional’ terms seems harder to grasp. The promotion of alcohol is widespread, yet the industry that produces it appears invisible, with product retail largely undertaken by other parties such as the ‘hospitality industry’ and supermarkets. The alcohol and tobacco industries are both responsible for non-communicable diseases [43], with alcohol also implicated in infectious diseases [44]. Both products cause multiple health harms including cancers, cardiovascular diseases and foetal damage. Alcohol additionally causes overdose, intoxication, violence, suicide, accidents, job loss, sexually transmitted infections, unintended pregnancy and family breakdown. As with smoking, many of the health harming impacts of drinking are cumulative, manifesting over the longer term, and like COVID-19, its impacts fall heaviest in socioeconomically disadvantaged communities [11]. Alcohol can also kill quickly [45].

A long tradition of drinking in some societies may account for an implicit acceptance, and the normalisation of alcohol harms, which may lead to a view that change is not possible. There is limited research on people’s perceptions of their own drinking and most of this is conducted with young people [46]. In such studies, as with the reinforcing effects of corporate social responsibility organisation messaging, personal risk is perceived as low [47]. A particular stereotypical and stigmatising view of the ‘alcoholic’ as ‘other’ serves to distance adult drinkers from recognition of risk or harm, regardless of their current health status or the quantity of alcohol actually consumed [48].

Reducing alcohol health harms inevitably means reducing the amount of the drug ethanol consumed, as this is the source of the harm [49]. Just as with tobacco, the most effective and cost-effective interventions are increasing the price of alcohol and reducing its physical availability and marketing [50]. Yet, alcohol remains a privileged, protected, and indeed ubiquitous product. The contrast with tobacco is increasingly stark. Alcohol has been defined as an ‘essential’ commodity in the UK and Australia during the COVID-19 pandemic, with off-sales protected and pubs the first places to open up as lockdowns eased [5153]. Alcohol industry actors are exceptionally effective at distracting attention from responsibility for harm, the extent of policy interference, and the similarities with tobacco.

Taking alcohol messaging upstream

There is gross asymmetry in the resources available in the research and public health arenas to produce, test and distribute high quality, well targeted, public-focused, messaging tailored for a range of media. It does look like something of a David and Goliath contest to oppose the interests of major transnational corporations and to intervene in an enjoyable well established social practice for many. Responsibility for the choice to drink rests with the individual, and somewhat less attention gets paid to the nature of the market, the information conditions under which that choice is exercised, and other constraints on individual choice. There are other asymmetries in play. The costs are borne by society, with the risks operating at individual, family, community and population levels, whilst corporations and their shareholders enjoy the benefits. Not drinking, or drinking less alcohol, can feel like opting out of an activity considered by others as central to relaxing and having fun.

The impoverished nature of public discourse on alcohol harms, means this is not an area where the public are currently clamouring to see more intervention. Marketing thus proceeds to lock in branded thinking about alcohol, in a vicious circle. Public opinion on alcohol and policy issues varies across time and place and can be influenced by public health interventions [54]. Existing evidence on mass media interventions is weak, and these are under-developed [55]. The ambition needed must match the sophistication of alcohol marketing in order to counter it. More needs to be done to understand how to get evidence-informed ideas out to the public and to create demand for population health measures.

Our work has identified the caution, scepticism and confusion with which ordinary drinkers receive advice from health professionals and the discomfort that health professionals experience in discussing drinking [5658]. Even for those convinced that their drinking is not a ‘problem,’ being asked about alcohol use in a health context can elicit negative emotions, including feeling judged or guilty, making open conversation difficult. In such circumstances a brief chat will rarely be any match for the huge corporate investment in encouraging drinking, and the wider and long running shaping of how we think about alcohol.

Corporate messaging has long experimented with active persuasion; shaping preferences to match values or solve problems. Messengers use a range of strategies to obtain favourable policy environments, build constituencies, sow doubt, creatively pursue “defactualization” taking advantage of what the audience wants to hear, with a careful eye to making this all credible and coherent [59]. Opportunities for attracting attention and practicing persuasion have expanded with the rise of digital social media, giving rise to formidable persuasion industries [60]. Some countries provide financial incentives for alcohol industry marketing through their taxation policies. For example, in the US, in 2017 the top 10 alcohol producers were exempted from paying taxes on US $1.5 billion for beer advertising alone [61]. Marketing to consumers is far from only being about persuading people to make purchase decisions, but analysing customers’ choices and behaviours so they are not even aware their buying decisions are being scrutinised and influenced [62]. Data analytics underpin what has been understood as surveillance capitalism [63, 64]. Social media offers publishing platforms funded by data-driven advertising which are free of the regulations to which other forms of media are subject, with no responsibility for accuracy of content.

Alcohol messaging must contend with how alcohol and alcohol harm can be reframed to evoke a different way of thinking about the personal and policy choices for health to be improved. This requires countermarketing that addresses ideas that products are new, aspirational, and identity, socially or even health enhancing. Learning from the tobacco experience makes many lessons available on how to make progress in improving population health [38, 65]. The nature of the threat to global health means that the situation will get worse unless we embrace the many challenges posed by alcohol marketing.

Alcohol research has historically been predominantly focused on particular populations and forms of problematized drinking that have stereotypical and highly stigmatised and stigmatising foundations [66, 67]. Alcohol science has been built around the fundamentally flawed concept of alcoholism and the associated treatment movement, in part due to industry involvement since the 1940s [68]. Similarly, alcohol health messaging is currently framed in an extreme close up on the drinker and whether or not they are consuming responsibly [69, 70]. The appearance of placing limits on individual choices is seized on by industry messaging, which additionally stereotypes the meddling, moralising ‘expert’ and nanny telling people what to do. We could begin to develop the science of alcohol messaging simply by introducing a wider angle which includes the corporate context and the drug ethanol as characters within the messaging.

Conclusion

Gerard Hastings wrote a key textbook on social marketing subtitled “why should the devil get all the best tunes?” [71] This rhetorical question invites us to invest more substantially in countermarketing ideas in improving health. Corporate actors, particularly in controversial sectors which damage health or the environment, are adept at myth making [72]. The alcohol companies, and the neoliberal fictions they contribute to and benefit from, position the state as Goliath, and the individual consumer as David. They use sophisticated tools of persuasion to ally themselves with David, producing a dystopian version of individual freedom which allocates responsibility for risk to individuals and renders invisible the processes of maximising shareholder wealth.

So many of the contemporary challenges in public health revolve around such contests with powerful global corporations, and alcohol is no different. The David and Goliath story has undergone many revisions in its re-telling to become a powerful metaphor for the potential of the plucky underdog. This metaphor is unhelpful if it keeps public health David on the back foot and stuck at the start of the contest. Alcohol marketing dominates people’s thinking about alcohol because we currently allow this to happen. We give corporations a license to operate, and we should look at the terms of the license, and revise them, to better protect public health. Some countries have complete bans on alcohol marketing and WHO recommends that such bans should be enforced where they exist, and comprehensive restrictions on advertising, sponsorship and promotion introduced where they do not. If that idea makes you uncomfortable, you might ask yourself why.

Acknowledgements

Not applicable.

Authors’ contributions

MM had the idea for this analysis, led the literature review and wrote the first draft of the paper. Both authors revised drafts of the paper and approved the final draft for submission. MM is the guarantor.

Authors’ information

Mary Madden (MM) is a Sociologist and Senior Qualitative Research Fellow working with Jim McCambridge (JM), Chair in Addictive Behaviours & Public Health on alcohol research at the University of York.

Funding

This work was completed under the auspices of financial support from the Wellcome Trust, via an Investigator Award to JM (200321/Z/15/Z). No funder played any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the Wellcome Trust.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Mary Madden, Email: Mary.Madden@york.ac.uk.

Jim McCambridge, Email: Jim.McCambridge@york.ac.uk.

References

  • 1.World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.
  • 2.Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, Venkateswaran V, Tapp AD, Forouzanfar MH, Salama JS, Abate KH, Abate D, Abay SM, Abbafati C, Abdulkader RS, Abebe Z, Aboyans V, Abrar MM, Acharya P, Adetokunboh OO, Adhikari TB, Adsuar JC, Afarideh M, Agardh EE, Agarwal G, Aghayan SA, Agrawal S, Ahmed MB, Akibu M, Akinyemiju T, Akseer N, Asfoor DHA, al-Aly Z, Alahdab F, Alam K, Albujeer A, Alene KA, Ali R, Ali SD, Alijanzadeh M, Aljunid SM, Alkerwi A', Allebeck P, Alvis-Guzman N, Amare AT, Aminde LN, Ammar W, Amoako YA, Amul GGH, Andrei CL, Angus C, Ansha MG, Antonio CAT, Aremu O, Ärnlöv J, Artaman A, Aryal KK, Assadi R, Ausloos M, Avila-Burgos L, Avokpaho EF, Awasthi A, Ayele HT, Ayer R, Ayuk TB, Azzopardi PS, Badali H, Badawi A, Banach M, Barker-Collo SL, Barrero LH, Basaleem H, Baye E, Bazargan-Hejazi S, Bedi N, Béjot Y, Belachew AB, Belay SA, Bennett DA, Bensenor IM, Bernabe E, Bernstein RS, Beyene AS, Beyranvand T, Bhaumik S, Bhutta ZA, Biadgo B, Bijani A, Bililign N, Birlik SM, Birungi C, Bizuneh H, Bjerregaard P, Bjørge T, Borges G, Bosetti C, Boufous S, Bragazzi NL, Brenner H, Butt ZA, Cahuana-Hurtado L, Calabria B, Campos-Nonato IR, Campuzano JC, Carreras G, Carrero JJ, Carvalho F, Castañeda-Orjuela CA, Castillo Rivas J, Catalá-López F, Chang JC, Charlson FJ, Chattopadhyay A, Chaturvedi P, Chowdhury R, Christopher DJ, Chung SC, Ciobanu LG, Claro RM, Conti S, Cousin E, Criqui MH, Dachew BA, Dargan PI, Daryani A, Das Neves J, Davletov K, de Castro F, de Courten B, de Neve JW, Degenhardt L, Demoz GT, Des Jarlais DC, Dey S, Dhaliwal RS, Dharmaratne SD, Dhimal M, Doku DT, Doyle KE, Dubey M, Dubljanin E, Duncan BB, Ebrahimi H, Edessa D, el Sayed Zaki M, Ermakov SP, Erskine HE, Esteghamati A, Faramarzi M, Farioli A, Faro A, Farvid MS, Farzadfar F, Feigin VL, Felisbino-Mendes MS, Fernandes E, Ferrari AJ, Ferri CP, Fijabi DO, Filip I, Finger JD, Fischer F, Flaxman AD, Franklin RC, Futran ND, Gallus S, Ganji M, Gankpe FG, Gebregergs GB, Gebrehiwot TT, Geleijnse JM, Ghadimi R, Ghandour LA, Ghimire M, Gill PS, Ginawi IA, Giref AZZ, Gona PN, Gopalani SV, Gotay CC, Goulart AC, Greaves F, Grosso G, Guo Y, Gupta R, Gupta R, Gupta V, Gutiérrez RA, GVS M, Hafezi-Nejad N, Hagos TB, Hailu GB, Hamadeh RR, Hamidi S, Hankey GJ, Harb HL, Harikrishnan S, Haro JM, Hassen HY, Havmoeller R, Hay SI, Heibati B, Henok A, Heredia-Pi I, Hernández-Llanes NF, Herteliu C, Hibstu DTT, Hoogar P, Horita N, Hosgood HD, Hosseini M, Hostiuc M, Hu G, Huang H, Husseini A, Idrisov B, Ileanu BV, Ilesanmi OS, Irvani SSN, Islam SMS, Jackson MD, Jakovljevic M, Jalu MT, Jayatilleke AU, Jha RP, Jonas JB, Jozwiak JJ, Kabir Z, Kadel R, Kahsay A, Kapil U, Kasaeian A, Kassa TDD, Katikireddi SV, Kawakami N, Kebede S, Kefale AT, Keiyoro PN, Kengne AP, Khader Y, Khafaie MA, Khalil IA, Khan MN, Khang YH, Khater MM, Khubchandani J, Kim CI, Kim D, Kim YJ, Kimokoti RW, Kisa A, Kivimäki M, Kochhar S, Kosen S, Koul PA, Koyanagi A, Krishan K, Kuate Defo B, Kucuk Bicer B, Kulkarni VS, Kumar P, Lafranconi A, Lakshmana Balaji A, Lalloo R, Lallukka T, Lam H, Lami FH, Lan Q, Lang JJ, Lansky S, Larsson AO, Latifi A, Leasher JL, Lee PH, Leigh J, Leinsalu M, Leung J, Levi M, Li Y, Lim LL, Linn S, Liu S, Lobato-Cordero A, Lopez AD, Lorkowski S, Lotufo PA, Macarayan ERK, Machado IE, Madotto F, Magdy Abd el Razek H, Magdy Abd el Razek M, Majdan M, Majdzadeh R, Majeed A, Malekzadeh R, Malta DC, Mapoma CC, Martinez-Raga J, Maulik PK, Mazidi M, Mckee M, Mehta V, Meier T, Mekonen T, Meles KG, Melese A, Memiah PTN, Mendoza W, Mengistu DT, Mensah GA, Meretoja TJ, Mezgebe HB, Miazgowski T, Miller TR, Mini G, Mirica A, Mirrakhimov EM, Moazen B, Mohammad KA, Mohammadifard N, Mohammed S, Monasta L, Moraga P, Morawska L, Mousavi SM, Mukhopadhyay S, Musa KI, Naheed A, Naik G, Najafi F, Nangia V, Nansseu JR, Nayak MSDP, Nejjari C, Neupane S, Neupane SP, Ngunjiri JW, Nguyen CT, Nguyen LH, Nguyen TH, Ningrum DNA, Nirayo YL, Noubiap JJ, Ofori-Asenso R, Ogbo FA, Oh IH, Oladimeji O, Olagunju AT, Olivares PR, Olusanya BO, Olusanya JO, Oommen AM, Oren E, Orpana HM, Ortega-Altamirano DDV, Ortiz JR, Ota E, Owolabi MO, Oyekale AS, P A M, Pana A, Park EK, Parry CDH, Parsian H, Patle A, Patton GC, Paudel D, Petzold M, Phillips MR, Pillay JD, Postma MJ, Pourmalek F, Prabhakaran D, Qorbani M, Radfar A, Rafay A, Rafiei A, Rahim F, Rahimi-Movaghar A, Rahman M, Rahman MA, Rai RK, Rajsic S, Raju SB, Ram U, Rana SM, Ranabhat CL, Rawaf DL, Rawaf S, Reiner RC, Reis C, Renzaho AMN, Rezai MS, Roever L, Ronfani L, Room R, Roshandel G, Rostami A, Roth GA, Roy A, Sabde YD, Saddik B, Safiri S, Sahebkar A, Salama JS, Saleem Z, Salomon JA, Salvi SS, Sanabria J, Sanchez-Niño MD, Santomauro DF, Santos IS, Santric Milicevic MMM, Sarker AR, Sarmiento-Suárez R, Sarrafzadegan N, Sartorius B, Satpathy M, Sawhney M, Saxena S, Saylan M, Schaub MP, Schmidt MI, Schneider IJC, Schöttker B, Schutte AE, Schwendicke F, Sepanlou SG, Shaikh MA, Sharif M, She J, Sheikh A, Shen J, Shiferaw MS, Shigematsu M, Shiri R, Shishani K, Shiue I, Shukla SR, Sigfusdottir ID, Silva DAS, Silva NTD, Silveira DGA, Sinha DN, Sitas F, Soares Filho AM, Soofi M, Sorensen RJD, Soriano JB, Sreeramareddy CT, Steckling N, Stein DJ, Sufiyan M'B, Sur PJ, Sykes BL, Tabarés-Seisdedos R, Tabuchi T, Tavakkoli M, Tehrani-Banihashemi A, Tekle MG, Thapa S, Thomas N, Topor-Madry R, Topouzis F, Tran BX, Troeger CE, Truelsen TC, Tsilimparis N, Tyrovolas S, Ukwaja KN, Ullah I, Uthman OA, Valdez PR, van Boven JFM, Vasankari TJ, Venketasubramanian N, Violante FS, Vladimirov SK, Vlassov V, Vollset SE, Vos T, Wagnew FWS, Waheed Y, Wang YP, Weiderpass E, Weldegebreal F, Weldegwergs KG, Werdecker A, Westerman R, Whiteford HA, Widecka J, Wijeratne T, Wyper GMA, Xu G, Yamada T, Yano Y, Ye P, Yimer EM, Yip P, Yirsaw BD, Yisma E, Yonemoto N, Yoon SJ, Yotebieng M, Younis MZ, Zachariah G, Zaidi Z, Zamani M, Zhang X, Zodpey S, Mokdad AH, Naghavi M, Murray CJL, Gakidou E. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2018;392(10152):1015–1035. doi: 10.1016/S0140-6736(18)31310-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Jernigan D, Ross CS. The Alcohol Marketing Landscape: Alcohol Industry Size, Structure, Strategies, and Public Health Responses. J Stud Alcohol Drugs, Supplement. 2020;(s19):13–25. https://apps.who.int/iris/handle/10665/274603. [DOI] [PMC free article] [PubMed]
  • 4.Aaker D. Building strong brands: London Simon & Schuster; 2010.
  • 5.Mindell JS, Reynolds L, Cohen DL, McKee M. All in this together: the corporate capture of public health. BMJ : British Medical Journal. 2012;345(dec17 1):e8082. doi: 10.1136/bmj.e8082. [DOI] [PubMed] [Google Scholar]
  • 6.McCambridge J, Hawkins B, Holden C. Vested interests in addiction research and policy. The challenge corporate lobbying poses to reducing society's alcohol problems: insights from UK evidence on minimum unit pricing. Addiction. 2014;109(2):199–205. doi: 10.1111/add.12380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Klaff O. Flip the script: getting people to think your idea is their idea. London: Piatkus; 2019. [Google Scholar]
  • 8.McCambridge J, Kypri K, Sheldon TA, Madden M, Babor TF. Advancing public health policy making through research on the political strategies of alcohol industry actors. J Public Health. 2020;42(2):262-9. 10.1093/pubmed/fdz031. [DOI] [PMC free article] [PubMed]
  • 9.Bruner C, Sjåfjell B. Corporate law, corporate governance and the pursuit of sustainability. In: Sjåfjell B, Bruner C, editors. The Cambridge handbook of corporate law, corporate governance and sustainability. Cambridge: Cambridge University Press; 2019. [Google Scholar]
  • 10.WHO . WHO to accelerate action to reduce the harmful use of alcohol. 2020. [Google Scholar]
  • 11.The Lancet Public Health Failing to address the burden of alcohol. Lancet Public Health. 2020;5(6):e297. doi: 10.1016/S2468-2667(20)30123-7. [DOI] [PubMed] [Google Scholar]
  • 12.World Health Organization (WHO) Global Strategy to Reduce Harmful Use of Alcohol. Geneva: WHO; 2010. [Google Scholar]
  • 13.Madureira Lima J, Galea S. Corporate practices and health: a framework and mechanisms. Glob Health. 2018;14(1):21. doi: 10.1186/s12992-018-0336-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Frayne J. Meet the people: why businesses must engage with public opinion to manage and enhance their reputations. London: Harriman House; 2013. [Google Scholar]
  • 15.Olins W. Brand New.: The Shape of Brands to Come: London Thames & Hudson; 2014.
  • 16.Bakan J. The new corporation: how 'good' corporations are bad for democracy: New York Vintage; 2020.
  • 17.Maani Hessari N, van Schalkwyk MC, Thomas S, Petticrew M. Alcohol industry CSR organisations: what can their twitter activity tell us about their independence and their priorities? A comparative analysis. Int J Environ Res Public Health. 2019;16(5):892. [DOI] [PMC free article] [PubMed]
  • 18.Petticrew M, Shemilt I, Lorenc T, Marteau TM, Melendez-Torres GJ, O'Mara-Eves A, et al. Alcohol advertising and public health: systems perspectives versus narrow perspectives. J Epidemiol Community Health. 2017;71(3):308–12. 10.1136/jech-2016-207644. [DOI] [PubMed]
  • 19.McCambridge J, Kypri K, Miller P, Hawkins B, Hastings G. Be aware of Drinkaware. Addiction. 2014;109(4):519–524. doi: 10.1111/add.12356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Maani Hessari N, Bertscher A, Critchlow N, Fitzgerald N, Knai C, Stead M, et al. Recruiting the "Heavy-Using Loyalists of Tomorrow": an analysis of the aims, effects and mechanisms of alcohol advertising, based on advertising industry evaluations. Int J Environ Res Public Health. 2019;16(21):4092. [DOI] [PMC free article] [PubMed]
  • 21.Maani Hessari N, Petticrew M. What does the alcohol industry mean by 'Responsible drinking'? A comparative analysis. J Public Health. 2018;40(1):90–7. 10.1093/pubmed/fdx040. [DOI] [PubMed]
  • 22.Petticrew M, Maani Hessari N, Knai C, Weiderpass E. How alcohol industry organisations mislead the public about alcohol and cancer. Drug Alcohol Rev. 2018;37(3):293–303. doi: 10.1111/dar.12596. [DOI] [PubMed] [Google Scholar]
  • 23.Petticrew M, Katikireddi SV, Knai C, Cassidy R, Maani Hessari N, Thomas J, Weishaar H. 'Nothing can be done until everything is done': the use of complexity arguments by food, beverage, alcohol and gambling industries. J Epidemiol Community Health. 2017;71(11):1078–1083. doi: 10.1136/jech-2017-209710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Michaels D. The triumph of doubt: dark money and the science of deception. Oxford: OXford University Press; 2020. [Google Scholar]
  • 25.Mitchell G, Lesch M, McCambridge J. Alcohol Industry involvement in the moderate alcohol and cardiovascular health trial. Am J Public Health. 2020;110(4):485–488. doi: 10.2105/AJPH.2019.305508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Golder S, Garry J, McCambridge J. Declared funding and authorship by alcohol industry actors in the scientific literature: a bibliometric study. Eur J Pub Health. 2020;30(6):1193–1200. doi: 10.1093/eurpub/ckaa172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.McCambridge J, Kypri K, Drummond C, Strang J. Alcohol harm reduction: corporate capture of a key concept. PLoS Med. 2014;11(12):e1001767. doi: 10.1371/journal.pmed.1001767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.McCambridge J, Mialon M, Hawkins B. Alcohol industry involvement in policymaking: a systematic review. Addiction. 2018;113(9):1571–1584. doi: 10.1111/add.14216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hawkins B, McCambridge J. Industry actors, think tanks and UK alcohol policy. Am J Public Health. 2014;104(8):1363–1369. doi: 10.2105/AJPH.2013.301858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Satz D. Why some things should not be for Sale: the moral limits of markets. Oxford: Oxford University Press; 2010. [Google Scholar]
  • 31.McGoey L. The unknowers: how strategic ignorance rules the world. London: Zed Books; 2019. [Google Scholar]
  • 32.Proctor RN. Agnotology: the making and unmaking of ignorance. Stanford, Cal: Stanford University Press; 2008. [Google Scholar]
  • 33.Oreskes N, Conway E. Merchants of doubt. London: Bloomsbury Press; 2010. [DOI] [PubMed] [Google Scholar]
  • 34.Bond L, Daube M, Chikritzhs T. Selling addictions: similarities in approaches between big tobacco and big booze. Australasian Med J. 2010;3(6):325–332. doi: 10.4066/AMJ.2010.363. [DOI] [Google Scholar]
  • 35.Jiang N, Ling PM. Reinforcement of smoking and drinking: tobacco marketing strategies linked with alcohol in the United States. Am J Public Health. 2011;101(10):1942–1954. doi: 10.2105/AJPH.2011.300157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.McCambridge J, Daube M, McKee M. Brussels declaration: a vehicle for the advancement of tobacco and alcohol industry interests at the science/policy interface? Tob Control. 2019;28(1):7–12. doi: 10.1136/tobaccocontrol-2018-054264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jiang N, Ling P. Vested interests in addiction research and policy. Alliance between tobacco and alcohol industries to shape public policy. Addiction. 2013;108(5):852–864. doi: 10.1111/add.12134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Marten R, Amul GGH, Casswell S. Alcohol: global health's blind spot. Lancet Glob Health. 2020;8(3):E329–EE30. doi: 10.1016/S2214-109X(20)30008-5. [DOI] [PubMed] [Google Scholar]
  • 39.Babor T, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, et al. Alcohol, no ordinary commodity: Research & Public Policy. Oxford: Oxford University Press; 2010. [Google Scholar]
  • 40.Adams P. Moral jeopardy: risks of accepting money from the alcohol, Tobacco and Gambling Industries Cambridge: Cambridge University Press; 2016. 10.1017/CBO9781316118689.
  • 41.McCambridge J, Morris S. Comparing alcohol with tobacco indicates that it is time to move beyond tobacco exceptionalism. Eur J Pub Health. 2019;29(2):200–1. 10.1093/eurpub/cky227. [DOI] [PMC free article] [PubMed]
  • 42.Collin J. Tobacco control, global health policy and development: towards policy coherence in global governance. Tob Control. 2012;21(2):274–280. doi: 10.1136/tobaccocontrol-2011-050418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Nishtar S, Niinisto S, Sirisena M, Vazquez T, Skvortsova V, Rubinstein A, et al. Time to deliver: report of the WHO independent high-level commission on NCDs. Lancet. 2018;392(10143):245–52. 10.1016/S0140-6736(18)31258-3. [DOI] [PubMed]
  • 44.Mialon M. An overview of the commercial determinants of health. Glob Health. 2020;16(1):74. doi: 10.1186/s12992-020-00607-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Chan M. Noncommunicable diseases: the slow motion disaster. Ten years in public health 2007–2017. Geneva: World Health Organisation; 2017. [Google Scholar]
  • 46.Morris S, Stewart D, Madden M, McCambridge J. A scoping review of qualitative research on perceptions of one's own alcohol use. Eur J Pub Health. 2020. 10.1093/eurpub/ckaa211. [DOI] [PubMed]
  • 47.Gough B, Madden M, Morris S, Atkin K, McCambridge J. How do older people normalise their drinking?: an analysis of interviewee accounts. Appetite. 2020;146:104513. doi: 10.1016/j.appet.2019.104513. [DOI] [PubMed] [Google Scholar]
  • 48.Madden M, Morris S, Stewart D, Atkin K, Gough B, McCambridge J. Conceptualising alcohol consumption in relation to long-term health conditions: exploring risk in interviewee accounts of drinking and taking medications. PLoS One. 2019;14(11):e0224706. doi: 10.1371/journal.pone.0224706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Kypri K, McCambridge J. Alcohol must be recognised as a drug. BMJ. 2018;362:k3944. doi: 10.1136/bmj.k3944. [DOI] [PubMed] [Google Scholar]
  • 50.WHO . Best buys' and other recommended interventions for the prevention and control of noncommunicable diseases: Updated (2017) appendix 3 of the global action plan for the prevention and control of noncommunicable diseases 2013–2020. 2017. [Google Scholar]
  • 51.Keric D, Stafford, J. Alcohol industry arguments for putting profit before health in the midst of a pandemic: The Western Australian experience. Drug Alcohol Rev. 2021;40:201-4. 10.1111/dar.13147. [DOI] [PMC free article] [PubMed]
  • 52.Finlay I, Gilmore I. Covid-19 and alcohol—a dangerous cocktail. BMJ. 2020;369:m1987. doi: 10.1136/bmj.m1987. [DOI] [PubMed] [Google Scholar]
  • 53.HM Government UK . Guidance: Closing certain businesses and venues in England. 2020. [Google Scholar]
  • 54.Brennan E, Schoenaker D, Durkin SJ, Dunstone K, Dixon HG, Slater MD, et al. Comparing responses to public health and industry-funded alcohol harm reduction advertisements: an experimental study. BMJ Open. 2020;10(9):e035569. doi: 10.1136/bmjopen-2019-035569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Young B, Lewis S, Katikireddi SV, Bauld L, Stead M, Angus K, Campbell M, Hilton S, Thomas J, Hinds K, Ashie A, Langley T. Effectiveness of mass media campaigns to reduce alcohol consumption and harm: a systematic review. Alcohol Alcohol. 2018;53(3):302–316. doi: 10.1093/alcalc/agx094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Madden M, Morris S, Atkin K, Gough B, McCambridge J. Patient perspectives on discussing alcohol as part of medicines review in community pharmacies. Res Social Adm Pharm. 2020;16(1):96–101. doi: 10.1016/j.sapharm.2019.03.145. [DOI] [PubMed] [Google Scholar]
  • 57.Quirk A, MacNeil V, Dhital R, Whittlesea C, Norman I, McCambridge J. Qualitative process study of community pharmacist brief alcohol intervention effectiveness trial: can research participation effects explain a null finding? Drug Alcohol Depend. 2016;161:36–41. doi: 10.1016/j.drugalcdep.2016.01.023. [DOI] [PubMed] [Google Scholar]
  • 58.Morris S, Madden M, Gough B, Atkin K, McCambridge J. Missing in action: insights from an exploratory ethnographic observation study of alcohol in everyday UK community pharmacy practice. Drug Alcohol Rev. 2019;38(5):561–568. doi: 10.1111/dar.12960. [DOI] [PubMed] [Google Scholar]
  • 59.Arendt H. Lying in politics: reflections on the Pentagon papers. New York Review of Books 17/8. 1971:30–9.
  • 60.McKevitt S. The persuasion industries: the making of modern Britain. Oxford: Oxford University Press; 2018. [Google Scholar]
  • 61.Strategies V. The sobering truth: incentivizing alcohol death and disability. New York: An NCD Policy Report; 2021. [Google Scholar]
  • 62.Hackley C. Marketing in context: setting the scene. Basingstoke: Macmillan; 2013. [Google Scholar]
  • 63.Zuboff S. Big other: surveillance capitalism and the prospects of an information civilization. J Inf Technol. 2015;30(1):75–89. doi: 10.1057/jit.2015.5. [DOI] [Google Scholar]
  • 64.Zuboff S. Surveillance capitalism a new priesthood. Esprit. 2019;5:63–77. doi: 10.3917/espri.1905.0063. [DOI] [Google Scholar]
  • 65.Casswell S. Vested interests in addiction research and policy. Why do we not see the corporate interests of the alcohol industry as clearly as we see those of the tobacco industry? Addiction. 2013;108(4):680–685. doi: 10.1111/add.12011. [DOI] [PubMed] [Google Scholar]
  • 66.Room R. Stigma, social inequality and alcohol and drug use. Drug and Alcohol Review. 2005;24(2):143–155. doi: 10.1080/09595230500102434. [DOI] [PubMed] [Google Scholar]
  • 67.Cunningham JA, McCambridge J. Is alcohol dependence best viewed as a chronic relapsing disorder? Addiction (Abingdon, England) 2012;107(1):6–12. doi: 10.1111/j.1360-0443.2011.03583.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Rubin JL. Shifting perspectives on the alcoholism-treatment movement 1940-1955. J Stud Alcohol. 1979;40(5):376–386. doi: 10.15288/jsa.1979.40.376. [DOI] [PubMed] [Google Scholar]
  • 69.Room R. Addiction and personal responsibility as solutions to the contradictions of neoliberal consumerism. Crit Public Health. 2011;21(2):141–151. doi: 10.1080/09581596.2010.529424. [DOI] [Google Scholar]
  • 70.L’Hôte E, Fond M, Volmert A. Seeing upstream: mapping the gaps between expert and public understandings of health in the United Kingdom. London: FrameWorks Institute; 2019. [Google Scholar]
  • 71.Hastings G. Social marketing: why should the devil get all the best tunes? Oxford: Elsevier; 2007. [Google Scholar]
  • 72.Ferns G, Amaeshi K, Lambert A. Drilling their own graves: how the European oil and gas Supermajors avoid sustainability tensions through mythmaking. J Bus Ethics. 2019;158(1):201–231. doi: 10.1007/s10551-017-3733-x. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from Globalization and Health are provided here courtesy of BMC

RESOURCES